The past year has continued the rapid evolution of diabetes technology across the monitoring, delivery, analytics, and patient-support domains. Improvements in continuous glucose monitoring (CGM) accuracy and wear-time options, widening use and regulatory expansion of automated insulin delivery (AID) systems, growth in connected insulin pens, maturation of digital therapeutics, and an influx of artificial intelligence (AI)-driven decision support tools have together shifted diabetes care toward tighter, more personalized, and more remote models of management. At the same time, device safety events, persistent affordability and access gaps, and data-interoperability and privacy challenges remind clinicians and policymakers that technology alone is not a panacea. This review summarizes the most important developments from last year (2025), highlights evidence from recent trials and regulatory actions, and discusses implications for practice and future directions.
Chatterjee et al. (Tue,) studied this question.